Tiragolumab esophageal cancer. The final remaining hope for Roche's anti-TIGIT MAb tiragolumab, a pivotal study in first-line liver cancer, is no more. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint which suppresses the immune response to cancer. Oct 19, 2025 · Tiragolumab added to Tecentriq plus Avastin did not improve progression-free survival in untreated advanced hepatocellular carcinoma, phase 3 data show. Jul 24, 2025 · Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals. CITYSCAPE is a phase 2, randomised, double-blind, placebo-controlled trial. Sep 28, 2023 · There were no objective responses with single-agent tiragolumab, but some patients experienced tumor shrinkage; combination tiragolumab plus atezolizumab showed promising activity in patients with immunotherapy-naive non–small cell lung cancer and esophageal cancer. Tiragolumab, a monoclonal antibody (mAb) targeting T cell immunoreceptor with Ig and ITIM domains (TIGIT), represents a novel approach in cancer immunotherapy. TIGIT, an immunological checkpoint receptor, suppresses T cell activation and promotes immune evasion in various cancers. Nov 25, 2024 · Tiragolumab is an investigational immune checkpoint inhibitor with an intact Fc region. May 13, 2022 · In the CITYSCAPE trial, we aimed to assess the preliminary efficacy and safety of tiragolumab plus atezolizumab (anti-PD-L1) therapy as first-line treatment for non-small-cell lung cancer (NSCLC). A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. . Tiragolumab, a monoclonal antibody (mAb) targeting T cell immunoreceptor with Ig and ITIM domains (TIGIT), represents a novel approach in cancer immunotherapy. npi lvinq czetm1 ncls t0z hyrx 6fd8i phwna gbs pe